Of particular interest is the fact that MET gene amplification and overexpression leads to resistance to anti-EGFR therapies in non-small cell lung cancer [19] and in brain tumors through receptor co-activation with EGFR [20]. The gene discussed is MET; the disease is non-small cell lung carcinoma.